Blog

Discover how immune checkpoint inhibitors like PD-1 and CTLA-4 blockers are transforming cancer treatment, including synergies with antibody-based therapeutics.

The Next-Gen Immuno-Oncology Conference 2024 in Boston featured advances in immunotherapy. Biointron shares insights driving future antibody-based treatments.

Infectious diseases like HIV and COVID-19 require novel therapies. Biointron shows how antibody drugs target pathogens to prevent infection and support recovery.

Discover how afucosylated antibodies enhance ADCC by increasing FcγRIIIa binding affinity, with clinical examples and applications in oncology and autoimmune disease therapy.

ADCs rely on diverse payloads. Biointron explores cytotoxic drugs and novel mechanisms that expand antibody-drug conjugate applications in oncology and beyond.

Multi-payload ADCs bring new strength to cancer therapy. Biointron explains how combining payloads boosts potency, reduces resistance, and improves patient outcomes.

AET Europe 2024 in London spotlighted antibody innovation. Biointron shares event takeaways on discovery, engineering, and development shaping the therapeutic pipeline.

BIO 2024 in San Diego showcased biotech innovation. Biointron reports highlights on antibody discovery, engineering, and collaborations shaping the future of biologics.

Antibody mimetics are engineered proteins that replicate antibody binding. Biointron explores their unique properties and potential advantages in therapy and research.

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

Autoimmune diseases demand precision therapy. Biointron explains how antibody drugs target RA, MS, and other conditions to reduce inflammation and improve outcomes.

Antibody-antibiotic conjugates fight resistant bacteria with precision. Biointron highlights how AACs combine antibody targeting with antibiotic power for infections.